Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer

2021 ◽  
Author(s):  
Nanor Sirab ◽  
Damien Drubay ◽  
Pascale Maillé ◽  
Tatiana Popova ◽  
Carine Ngo ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Intratumoral Heterogeneity

Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 4512-4512
Author(s):  
David Liu ◽  
Philip Abbosh ◽  
Daniel Keliher ◽  
Brendan Reardon ◽  
Kent William Mouw ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Overall Survival ◽  
Bladder Cancer ◽  
Immune Checkpoint ◽  
Intratumoral Heterogeneity ◽  
Post Treatment ◽  
Cox Proportional Hazards Model ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

4512 Background: Biomarkers of survival and resistance in chemotherapy-resistant muscle-invasive bladder cancer (MIBC) are not well-characterized, but may inform management in this setting. Methods: Matched pre- and post-neoadjuvant cisplatin-based chemotherapy (NAC) tumor samples were obtained from 30 MIBC patients with gross residual disease (≥ pT2) at cystectomy, followed by whole exome sequencing of these “trios” (pre- and post-NAC tumor with matched germline samples). Phylogenetic analysis of matched tumor samples was performed to identify subclones, their associated mutations, and the corresponding enrichment in post-treatment tumors. Intratumoral heterogeneity was assessed by the proportion of mutations that were subclonal; the number of inferred subclones; and associated with overall survival using a Cox Proportional Hazards model. Results: Increased proportion of subclonal mutations in post-treatment tumors was associated with worse overall survival (HRR 1.86 [95% CI 1.12-3.06], p = 0.02), whereas pre-treatment proportion of subclonal mutations was only borderline statistically significant (HRR 1.48 [95% CI 0.99-2.20], p = 0.052). The total number of inferred tumor subclones in pre- or post-treatment tumor (or both) was associated with overall survival (HRR 1.60 [95% CI 1.05-2.43], p = 0.03), interpreted as a 60% increase in death rate per additional inferred subclone. While no single gene was statistically significantly enriched for new alterations in the post-chemotherapy resistant samples, we observed new post-treatment amplifications in cell-cycle genes ( E2F3, c-JUN), biallelic events in cell-cycle regulators ( FBXW7), and amplification of immune checkpoint genes ( PDL1/2). Conclusions: These results suggest that intratumoral heterogeneity (particularly post-therapy) predicts survival in a chemotherapy-resistant cohort. Further, alterations in cell cycle regulation may contribute to the mechanism of chemotherapy resistance. Finally, we observe evidence of immune checkpoint gene amplification post-treatment, suggesting that testing immune checkpoint blockade during NAC or, in high risk patients, following NAC may be warranted.

Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants

2019 ◽  
Vol 75 (1) ◽  
pp. 18-22 ◽  
Author(s):  
Joshua I. Warrick ◽  
Gottfrid Sjödahl ◽  
Matthew Kaag ◽  
Jay D. Raman ◽  
Suzanne Merrill ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Molecular Subtypes ◽  
Intratumoral Heterogeneity

Intratumoral Heterogeneity of DNA Indexes in Transitional Cell Bladder Cancer: Relation to Tumor Histology

1991 ◽  
Vol 20 (4) ◽  
pp. 311-314 ◽  
Author(s):  
P.K. Lipponen ◽  
M.J. Eskelinen ◽  
S. Nordling
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell ◽  
Intratumoral Heterogeneity ◽  
Tumor Histology ◽  
Cell Bladder Cancer ◽  
Transitional Cell Bladder Cancer

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-invasive Bladder Cancer

Urology ◽  
2020 ◽  
Author(s):  
Jessica Marinaro ◽  
Alexander Zeymo ◽  
Jillian Egan ◽  
Filipe Carvalho ◽  
Ross Krasnow ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Racial Disparities ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer

2020 ◽  
Author(s):  
Xuan-Mei Piao ◽  
Ho Won Kang ◽  
Pildu Jeong ◽  
Young Joon Byun ◽  
Hee Youn Lee ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

775: Cell Culture Proteome Identifies CXCL 1 as a Secreted Marker and Mediator for the Tumor Invasion of Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 260-260 ◽  
Author(s):  
Hiroaki Kawanishi ◽  
Yoshiyuki Matsui ◽  
Toshinari Yamasaki ◽  
Takeshi Takahashi ◽  
Hiroyuki Nishiyama ◽  
...  
Keyword(s):  
Cell Culture ◽  
Bladder Cancer ◽  
Tumor Invasion

774: Improvement of Anti-Angiogenic and Anti-Tumorigenic Efficacy of Thrombospondin-1 by PPAR┌ Ligands in Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 259-259
Author(s):  
Thomas Nelius ◽  
Hanua Huang ◽  
Stephanie Filleur ◽  
Steven C. Campbell ◽  
Werner de Riese ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Thrombospondin 1 ◽  
Ppar Ligands

769: Matrix Metalloproteinase Polymorphisms are associated with Bladder Cancer Invasiveness

2007 ◽  
Vol 177 (4S) ◽  
pp. 258-258
Author(s):  
A. Karim Kader ◽  
Jun Liu ◽  
Una Shao ◽  
Colin P.N. Dinney ◽  
Jie Lin ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Matrix Metalloproteinase ◽  
Cancer Invasiveness

764: Differential Expression of RAL GTPases and their Effectors in Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 256-256
Author(s):  
Steven Smith ◽  
Gary Oxford ◽  
Dan Theodorescu
Keyword(s):  
Bladder Cancer ◽  
Differential Expression ◽  
Ral Gtpases
Sign in / Sign up

Export Citation Format

Share Document